Anus:

None at this time

Brain:

UMCC 2-66, Phase I Study of Concurrent Temozolomide and 3D Conformal Radiotherapy Dose Escalation for Treatment of Primary Glioblastoma Multiforme
Patient Population: Patients with newly diagnosed histologically-confirmed supratentorial WHO grade IV gliomas including glioblastoma multiforme and gliosarcoma.
Study available at the following clinic(s): University of Michigan

UMCC 3-23, Phase I Study of Concurrent Gemcitabine and Radiotherapy (RT) for Malignant High Grade Gliomas
Patient Population: Patients with histologically proven supra-tentorial WHO grade III or IV malignant glioma.
Study available at the following clinic(s): University of Michigan

UMCC 3-32, PET in Whole Brain Radiation
Patient Population: Patients who require prophylactic whole brain radiation as part of their routine medical treatment.
Study available at the following clinic(s): University of Michigan

UMCC 2003-083, MRI Study of Radiation-Induced Damage to the White Matter and Blood-Brain-Barrier
Patient Population: Three categories of patients will be enrolled. Patients who will have prophylactic cranial irradiation with no evidence of any brain malignancy; patients receiving partial brain irradiation with low-grade gliomas and are at risk for developing late radiation effects; patients receiving partial brain irradiation to benign tumors such as pituitary adenomas, supratentorial meningioma, or craniopharyngiomas.
Study available at the following clinic(s): University of Michigan 

RTOG 0424, A Phase II Study of Temozolomide-based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas
Patient Population: Patients with histologically proven supratentorial WHO grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
Study available at the following clinic(s): University of Michigan

Breast: 

UMCC 2004-020, Partial Breast Irradiation Using Accelerated Intensity Modulated Radiotherapy in Early Stage Breast Cancer after Breast-Conserving Surgery.
Patient Population: Patients with unifocal histologically proven breast cancer.
Study available at the following clinic(s) : University of Michigan

RTOG 9804, Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.
Patient Population: Patients with unicentric mammographically detected DCIS.
Study available at the following clinic(s): University of Michigan, Foote Hospital, VA Ann Arbor Healthcare System, Ingham Regional Medical Center

NCIC MA.20, A Phase III Study of Regional Radiation Therapy in Early Breast Cancer.
Patient Population: Patients with histologically proven invasive carcinoma of the breast.
Study available at the following clinic(s): Ingham Regional
Medical Center and University of Michigan

Partial Breast Irradiation with the Use of High Dose Rate Brachytherapy as the Sole Radiation Treatment in Early Stage Breast Cancer
Patient Population: Patients undergoing lumpectomy for Stage I histologically confirmed non-lobular, non EIC (extensive intraductal component) carcinoma of the breast.
Study available at the following clinic(s): Providence Cancer Center and Assarian Cancer Center, Ingham Regional Medical Center, Foote Hospital

Cervix:

MRI for Brachytherapy Radiation Treatment Planning in Patients with Cervix Cancer
Patient Population: Patients with histologically confirmed primary or recurrent cervical cancer.
Study available at the following clinic(s): Providence Cancer Center, Assarian Cancer Center

UMCC 2-54, A Pilot Study to Quantify and Compare the Volume of Target and Normal Tissue Irradiated with the Addition of Sequential MRI-CT Fusion, Video Fluoroscopy, and Daily Portal Imaging to Radiation Therapy Treatment Planning for Cervical Cancer.
Patient Population: Patients with histologically confirmed primary or recurrent cervical cancer.
Study available at the following clinic(s): University of Michigan

Head and Neck:

UMCC 2-21, Optimized Intensity Modulated Irradiation for Head and Neck Cancer.
Patient Population: Patients with histologically confirmed invasive cancer of the head and neck.
Study available at the following clinic(s): University of Michigan

Imaging:

UMCC 9974, Pilot Study of On-Line Imaging During Radiotherapy.
Patient Population: All patients with biopsy-proven head and neck, breast, lung, abdominal, or pelvic cancers who are eligible for radiation therapy and who require the use of a CT scan for radiation planning. Enrollment currently open for abdominal and breast patients only.
Study available at the following clinic(s): University of Michigan.

Liver:

 UMCC 2001-008, A Phase II Study of High Dose Radiation (Combined with Hepatic Arterial Floxuridine) for Patients with Unresectable Intrahepatic Malignancies.
Patient Population: Patients with biopsy-proven unresectable intrahepatic malignancies.
Study available at the following clinics(s): University of Michigan

UMCC 2-8, Phase I Trial of Dose Escalated Whole Liver Irradiation with Hepatic Arterial Floxuridine/Leucovorin/Streptozotocin Chemotherapy Followed Subsequently by Chemoembolization with Mitomycin-C for Patients with Neuroendocrine Hepatic Metastases
Patient Population: Patients with histologically-proven neuroendocrine tumors (carcinoid or islet cell) with dominance of liver metastases.
Study available at the following clinic(s): University of Michigan

UMCC 2-14, A Phase I Whole Liver Radiation Dose Escalation Trial Using Amifostine as a Radioprotective Agent.
Patient Population: Patients with histological or AFP confirmation of malignancy and radiographic evidence of diffuse hepatic involvement.
Study available at the following clinics(s): University of Michigan

UMCC 2003-072, A Pilot Study of Radiation-Induced Liver Disease Onset Using CT-based Perfusion.
Patient Population: Patients planning to undergo a course of radiation therapy for intrahepatic malignancies.
Study available at the following clinic(s): University of Michigan

UMCC 2003-081, Assessment of Liver Function in Patients Undergoing Hepatic Irradiation
Patient Population: Patients planning to undergo a course of radiation therapy for intrahepatic malignancies.
Study available at the following clinic(s): University of Michigan

Lung:

UMCC 2003-073, A Phase I/II Randomized Trial in Radiation Dose Escalation and Timing of Concurrent Chemotherapy for Patients with Stage III Unresectable/Inoperable Non-Small Cell Lung Cancer.
Patient Population: Patients with histologically-proven inoperable, non-small cell lung cancer.
Study available at the following clinic(s): University of Michigan, VA Ann Arbor Healthcare System, Providence Cancer Center, Assarian Cancer Center

RTOG 0212, A Phase II/III Randomized Trial of Two Doses (Phase III-Standard vs. High) and Two High Dose Schedules (Phase II-Once vs. Twice Daily) for Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer.
Patient Population: Patients with histologic or unequivocal cytologic proof of stage I-IIIB small cell lung cancer.
Study available at the following clinic(s): University of Michigan, VA Ann Arbor Healthcare System, Foote Hospital, Alpena General Hospital

RTOG 0214, A Phase III Comparison of Prophylactic Cranial Irradiation versus Observation In Patients with Locally Advanced Non-Small Cell Lung Cancer.
Patient Population: Patients with newly diagnosed stage IIIA or IIIB non-small cell lung cancer having completed definitive locoregional therapy.
Study available at the following clinic(s): University of Michigan, VA Ann Arbor Healthcare System, Foote Hospital, Alpena General Hospital

Pancreas:

UMCC 2003-082, Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer.
Patient Population: Patients with cytologic or histologic confirmation of carcinoma arising in the pancreas. Excludes patients with neuroendocrine tumors.
Study available at the following clinic(s): University of Michigan

Prostate: 

UMCC 2003-067, A Randomized Phase II Trial of Urethral Sparing Intensity-Modulated Radiation Therapy (US-IMRT) compared to Standard 3D Conformal Radiation Therapy (3D-CRT) for Low Risk Prostate Cancer Patients to Improve Quality of Life (QoL) within the Urinary Domain as Measured by the Expanded Prostate Cancer Index Composite (EPIC)
Patient Population: Patients who have a diagnosis of low-risk prostate cancer and have chosen external beam radiation therapy as the primary treatment.
Study available at the following clinic(s): University of Michigan

RTOG p0126, A Phase III Randomized Study of High Dose 3D-CRT versus Standard Dose 3D-CRT in Patients Treated for Localized Prostate Cancer
Patient Population: Patients with biopsy-proven non-metastatic prostate cancer who have chosen external beam radiation therapy as the primary treatment.
Study available at the following clinic(s): University of Michigan, Foote Hospital, VA Ann Arbor Healthcare System

CTSU JPR.7, A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients with Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer.
Patient Population: Patients with histologically or cytologically confirmed adenocarcinoma of the prostate who were previously treated with pelvic radiotherapy and now have a rising PSA.
Study available at the following clinic(s): University of Michigan,Foote Hospital

Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI based Treatment Planning
Patient Population: Patients with histologically confirmed diagnosis of prostate cancer.
Study available at the following clinic(s): Providence Cancer Center, Assarian Cancer Center